Mofetil-mykophenolate administration in recipients of allogenic kidney in different post-transplantation periods
Abstract
MMF was administrated in 15 recipients of allogenic kidneys at various periods after the operation (1 to 48 months). Indications to MMF were: acute rejection (7 patients), chronic rejection (6 patients), CyA-nephropathy (1 patient) and unclear nephropathy (1 patient). MMF was effective in 12 patients. Our experience with MMF allows us to conclude, that: 1) MMF is effective both in acute and chronic rejection, 2) MMF is much more effective at late period after transplantation, than at the early one. Only 2 patients had a diarrhea which was cut off after these patients were conversed on after meal taking MMF.
About the Authors
M. M. Kaabak
Отдел трансплантации органов, лаборатория клинической иммунологии Российского научного центра хирургии РАМН
Russian Federation
Russian Federation
V. A. Goriainov
Отдел трансплантации органов, лаборатория клинической иммунологии Российского научного центра хирургии РАМН
Russian Federation
Russian Federation
E. A. Molchanova
Отдел трансплантации органов, лаборатория клинической иммунологии Российского научного центра хирургии РАМН
Russian Federation
Russian Federation
References
1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet, 1995; 345; 1321-1325.
2. Sollinger H.W. for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allografts recipients. Transplantation, 1995; 60; 225-232.
3. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomisied, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.
4. Mathew T.H. for The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term randomisied multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at 3 years. Transplantation, 1998; 65: 1450-1454.
5. Pretagostini R., Rossi M., Berloco P. et al. Mofetil mycophenolate in renal transplantation. Abtsr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1, 5.
6. Weir V.R., Anderson L., Fink J.C. et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation, 1997; 64: 1706-1710.
7. Hueso M., Bover J., Seron D. et al. Low-dose cyclosporine and mycophenolate mofetil in renal allografts recipients with suboptimal renal function. Transplantation, 1998; 65.
8. Sheketa M., McGrath J. The safety and efficacy of complete cyclosporine withdrawal and substitution with mycophenolate mofetil in patients with chronic allograft nephropathy. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.
9. Oyo A.O., Meier-Kriesche H.-U. et al. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.
10. Land W., Schneerberger H., Stumpfig L. et al. Long-term application of mycophenolate mofetil monotherapy: safe and efficacious maintenance immunosuppression in kidney transplanted patients. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.
11. Grinyo J.M. Place of mycophenolate mofetil. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.
12. McGrath J., Shehata M. Complete withdrawal of cyclosporin in chronic allograft nephropathy: a randomised prospective trial of conversion to mycophenolate mofetil or tacrolimus. Abstr. of Intern. Congr. of the Transplant. Soc.,Rome, 2000, aug. 27 - sept. 1.
13. Hardwick L., Savatta S., Book B. et al. Effect of mycophenolate mofetil (MMF) on anti-CMV serologic response after renal transplantation. Abstr. of Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.
Review
For citations:
Kaabak M.M., Goriainov V.A., Molchanova E.A. Mofetil-mykophenolate administration in recipients of allogenic kidney in different post-transplantation periods. Nephrology and Dialysis. 2001;3(1):52-56. (In Russ.)
Views:
7
Email this article 